Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology
Volume 4, Issue 2, Pages 54-58
Clinical Gastroenterology

The Equivalence of Two Open Therapeutic Regimens of Cimetidine in the Treatment of Acute Duodenal Ulcer Disease: A Canadian Multicentre Trial

H Navert,1 AP Archambault,2 IGM Cleator,3 NB Hershfield,4 EJ Prokipchuk,5 and ABR Thomson6

1Centre Hospitalier Universitaire, University of Sherbrooke, Sherbrooke, Quebec, Canada
2Centre Hospitalier Maisonneuve-Rosemont, University of Montreal, Montreal, Quebec, Canada
3St Paul’s Hospital, University of British Columbia, Vancouver, British Columbia, Canada
4Foothills Hospital, University of Calgary, Calgary, Alberta, Canada
5St Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada
6University of Alberta Hospital, University of Alberta, Edmonton, Alberta, Canada

Received 27 April 1988; Accepted 7 April 1989

Copyright © 1990 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


One hundred and four patients completed a multicentre study comparing the standard cimetidine regimen of 300 mg qid with cimetidine 600 mg bid in the treatment of acute duodenal ulcer. Both dosage regimens were effective in alleviating symptoms. At the two- and four-week assessments a significantly greater decrease in frequency, duration and severity of night time pain was recorded in the 600 mg bid group (P<0.05). The healing rates were equivalent in both treatment groups. After eight weeks of treatment, 96% of the patients had healed in each treatment group. Cimetidine 600 mg bid may represent a useful alternative therapeutic regimen to the standard 300 mg qid dosage in patients with symptomatic acute duodenal ulcer disease.